Interleukine-33 and Lipid Profile in Cardiovascular Diseases Patients and Healthy Subjects by Al-iqabi, Muntaha Abass
ISSN 2321-807X 
1308 | P a g e                                                       J a n u a r y  3 1 ,  2 0 1 4  
Interleukine-33 and Lipid Profile in Cardiovascular Diseases     Patients 
and Healthy Subjects 
Dr. Muntaha Abass Lafta 
Department of Chemistry, College of Education for Pure Sciences- Ibn-Alhaitham, Baghdad University, 
Baghdad, Iraq 
dr_muntahaabass@yahoo.com 
ABSTRACT 
Interleukine-33 (IL-33), a newly described member of the IL-1 family, is expressed by many cell types, but the precise 
source of IL-33 remains so far unclear. IL-33 is implicated in the pathogenesis of many diseases. However, IL-33 is a 
multifaceted mediator with both pro- and anti- inflammatory activities, it presents an extracellular and nuclear – bound from, 
each of them performing distinct activities of their own. 
The objective of the present study is to evaluate the serum level of IL-33 in patients suffering from diverse cardiovascular 
diseases (CVD) with different body mass index (BMI), and to compare those with healthy control subjects with matched BMI. 
In an attempt to find the contribution of IL-33 and obesity to the pathogenesis of cardiovascular diseases. 
The study was carried on( 30) patients with cardiovascular diseases, who were divided to three equal groups according to 
their BMI as G1 with BMI (20-24.9), G2 with BMI (25-29.9) and G3 with BMI > 30. Healthy individuals were included (10) for 
each patients group matched BMI and age. All subjects performed serum tests for lipid profile and IL-33 after an overnight 
fast. 
The results showed a significant rise in total cholesterol and triglyceride only for G3 when compared to their healthy 
control, while significant differences were found for LDL, VLDL and IL-33 for all patient groups when compared with their 
matched age and BMI control groups. Also a significant elevation for G3 compared to G1 and G2 in triglyceride, LDL and IL-
33 were found. 
A conclusion could be made that IL-33 and LDL are significantly affected by BMI in patients groups only and not in the 
control subjects. This confirms the synergistic effect of the obesity and cardiovascular events on IL-33, while no effect of the 
disease could be detected from the present study. 
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INTRODUCTION  
Cardiovascular disease (CVD) is a class of disease that involves the heart, blood vessels or both. Obesity is often linked 
to diseases that involve the heart, the blood vessels or both [1]. 
Obesity is the commonest nutritional disorder in affluent societies [2]. Obesity has become a leading health concern 
because this condition is a chronic, complex, multifactorial disease in which a person's weight is ≥20% of the ideal weight 
for a given height [3]. Although not a direct measure of obesity, the most widely used method to gauge obesity is the Body 
Mass Index (BMI) which is equal to Weight / Height 
2
   in (Kilogram / Meter
2 
).[4] 
Intreleukine-33 (IL-33) is the latest accrual to the IL-1 cytokine superfamily. Although, this super family encompasses 
structurally related cytokines IL-1α, IL-1β, IL-1Ra (IL-1 receptor antagonist), IL-18 and IL-33. IL-33, IL-1β and IL-18 are 
rated as primordial inflammatory cytokines, whereas IL-Ra is an anti-inflammatory peptide which dampens excessive 
activities of IL-1β. IL-33, in its own turn, stands out as a cytokine with dual function. Through the activation of the ST2L 
membrane receptor complex it acts as a traditional conceived cytokine. [5] 
Interleukine-33, the novel member of the IL-1 cytokine superfamily, was 
suggested to take part in the anti-atherogenic response by mediating the Th1-to-Th2 switch of the immune reactions. 
However, IL-33 is multifaceted mediator with both pro- and anti- inflammatory activities, IL-33 presents both an 
extracellular (cytokine-like) and a nuclear – bound (transcription factor-like) from, each of them performing distinct 
activities of their own. [6] 
 
However IL-33 has shown various protective effects in cardiovascular diseases such as atherosclerosis, obesity, type-2 
diabetes and cardiac remodeling. Thus the effects of IL-33 are either pro-or-anti-inflammatory depending on the disease 
and the model [7]. The C-terminal fragment of IL-33 is the only cytokine that has been shown to bind the receptor ST2L. 
The IL-33/ST2L complex subsequently associates with 1L-receptor accessory protein (IL-1RAcP) thereby activating 
intracellular molecules in the nuclear factor-kB (NF-kB) and mitogen activated protein kinase (MAP kinase) signaling 
pathways. This activation derives the production of type2 cytokines from polarized Th2 cells. [8] 
It has been shown that IL-33 expressed in various human tissues, particularly those which are in contact with environmental 
conditions, either external, or internal, but the most importantly that IL_33 expression has been documented in coronary 
artery endothelium, coronary artery smooth muscle cells, cardiac fibroblast and adipocytes. [9] 
The aim of the present study was to evaluate serum interleukin-33 in normal weight and obese cardiovascular patients 
and healthy population, since obesity is one of the most important modifiable risk factors for cardiovascular disease 
(CVD).  
METHADOLOGY 
Sampling 
      Ten ml of venous blood was placed in a plain tube ( no anticoagulant ), which was taken from groups attending, left for 
(15) at room temperature, then centrifuged (at 2500 rpm for 10 min) to get the serum, which was stored about (-20°C) 
unless used immediately. 
The samples were collected from cardiovascular patients their ages ranged between (33-67) years, at the diagnosis time 
at (Ibn- Albetar Specialized Hospital/Baghdad) during the period from December 2012 to April 2013. 
None of the control were atherosclerotic vascular disease, diabetic, renal disease, history of allergy, alcoholic consumption 
and heavy smoker. 
The samples have been classified into four groups as follow: 
1-Control group: includes (10) healthy (both sex) for each group according to BMI, ages range (25-63) years and no previous 
diseases which may interfere with the parameters analyzed in the study. 
2-Patients group were divided into three groups according to BMI: 
A- Group (1): includes (10) patients (both sex) with BMI (20-24.9) Kg/m
2
     B- Group (2): includes (10) patients (both sex) with 
BMI (25-29.9) Kg/m
2
            C- Group (3): includes (10) patients (both sex) with BMI (30 to over) Kg/m
2
          
METHODS 
Lipid profile analysis:- 
-Fractions of serum lipids were performed using read kit from Bio Merieux A.S., France as follow:   
-Serum total cholesterol was determined by the enzymatic method employing a series of enzymes (i.e. easterase, oxidase 
and peroxidase) according to the method of Richmond. [10] 
-Serum triglyceride was determined colometrically by enzymatic method using a series of enzymes (i.e. lipase, glycerol 
kinase, glycerol-3-phosphate oxidase and peroxidase) [11] 
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-Serum HDL was determined after precipitation of chylomicron, VLDL and LDL contained in the serum samples by 
addition of 4% phosphotungestic acid in the presence of magnesium chloride, the supernatant obtained after 
centrifugation contain the HDL which was determined according to Burstein, et.al.(1970).[12] 
-Serum LDL was determined indirectly by the use of Friedwald Formula [13] 
Interleukine-33 (IL-33) determination:- 
Interleukine-33 has been estimated by using enzyme immunoassay (ELISA) technique using the manufacturer instruction 
as supplied with kit from Ray Bio®   Human. [14] 
 Body Mass Index :-was calculated according to the relation: 
Weight (Kg) / [Height (M)]
 2 
   [15] 
Fost et.al suggested that BMI of (18.5-24.9) indicate a person of normal weight. A person with BMI of (25-29.9) is 
overweight, while a person with BMI of >30 is obese. [16] 
The body mass index (BMI), or Quetelet index, is a measure for human body shape based on an individual's mass and 
height.  
Devised between 1830 and 1850 by the Belgian polymath Adolph Quetelet during the course of developing "social 
physics", (15) it is defined as the individual's body mass divided by the square of their height- with the value universally 
being in units of Kg/m
2
.  
BMI = mass (kg)/ [height (m)]
 2 
 
STATISTICAL ANALYSIS 
The results were expressed as Mean± SD. Student- test was used to show the differences between groups variation was 
considered significant when P- values are < 0.05. The correlation coefficient (r) test is used to describe the association 
between the different studied parameters. 
RESULTES 
In table (1) there were no significant differences between mean± SD values of patient groups and their control in HDL 
P>0.05, but there were a significant differences in total cholesterol and triglyceride only for G3 and their control. On the 
other hand significant differences were found for all studied groups with their control for LDL, VLDL and IL-33. 
For the other part of the same table, there were a significant differences for G3 compared to G1 and G2 in triglyceride, 
LDL and IL-33. 
 
Table (1): All parameters involved in the study for all patient groups and control groups (Mean±SD) according to 
BMI 
G3 
BMI > 30 Kg/m
2
 
G2 
BMI (25-29.9) Kg/m
2
 
G1 
BMI (20-24.9) Kg/m
2
 
 
Control Patient Control Patient Control Patient            Groups                
 
Parameters 
 
4.02±  0.8 
                * 
4.72± 1.18    
 
4.01± 0.2 
 
4.12± o.43 
 
3.92± 0.11     
 
4.21 ± 0.3 
Total cholesterol 
Mmol/L         
 
1.29± 0.36 
             @* 
1.81± 0.62  
 
1.12± 0.81 
 
1.32± 0.31 
 
1.03± 0.21     
 
1.02± o.37        
Triglyceride        
Mmol/L            
 
1.27± 0.1 
 
1.0± 0.19 
 
1.32± 0.04 
 
1.31 ±0.38 
 
1.12 ±0.29 
 
1.01± 0.03 
HDL                
Mmol/L            
 
2.73± 0.21 
            @* 
3.92± 0.8  
 
2.10 ±0.09 
 
3.02 ±0.08 *  
 
 2.07±0.81              
 
3.12± 0.02* 
LDL                
Mmol/L            
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0.55± 0.17 
              * 
0.81± 0.36 
 
0.51 ±0.13 
 
o.70± 0.88  * 
 
0.49±  0.10   
 
 0.71± 1.2*              
VLDL              
Mmol/L            
 
14.3± 1.5 
               @* 
23.72± 2.54 
 
13.7± 1.1 
 
19.38± 2.3 * 
 
14.28± 0.89  
 
10.6± 0.22*       
IL-33              
Pg/ml              
 
 *Significant at P≤ 0.05 when compared to their matching controls   .       .   Significant at P≤0.05 for patients G3 as compared to 
G1 and G2 @
 
Fig (1-3) shows the presence of correlation between BMI and IL-33, in three patient groups 
 
 
BMI 
 
 
BMI 
   
 
IL-33 
IL-33 
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BMI 
                               SERIES 1 : control 
                               SERIES 2 :studied group 
 
DISCUSSION    
From the results of the present study which showed higher levels of IL-33 with higher LDL levels especially in obese 
patients with cardiovascular disease are consisted with reported date stated that expression of IL-33 and its receptor ST2 
in human adipose tissue is 
predominantly detectable in endothelial cells and increased by severe obesi ty indicat ing an autocrine 
act ion.  Thus,  the adipose t issue microvasculature could participate in obesity-associated inflammation and related 
complications via IL-33/ST2. [17]. Having entered the vascular wall, atherogenetic lipoprotein particles, such as low-density 
lipoprotein (LDL) and very low density lipoprotein (VLDL), are retained with the extracellular matrix. This entrapment 
occurs by the interaction of negatively charged sulphate groups of matrix proteoglycans and positively charged domains 
of apolipoprotien B-100. LDL particles within the arterial wall are highly susceptible to oxidation and acylation. [18]. 
In vitro IL-33 has been shown to constrain macrophage foam cell formation by decreasing modified (i.e. 
acetylated or oxidized; AcLDL or OxLDL) low- density lipoprotein uptake [19].Given these properties, it is conceivable 
that natural IgM antibodies play a protective role in atherosclerosis [20]. 
The expression of ST2L, the membrane-bound form of IL-33 receptor on macrophages, is a sine qua non for this 
cytokines atheroprotective effects. Actually, in ST2 macrophages that are completely devoid of this receptor protein, IL-33 
by itself can neither decrease the uptake of LDL nor reduce intracellular cholesterol levels [19]. This concept is supported 
by the clinical finding that the IL-33 decoy receptor sST2 was elevated in serum early after acute myocardial infarction 
(AMI), and correlated with creatine kinase and inversely correlated with left ventricular fraction [21], and elevated levels of 
sST2 were significant predictor of mortality or future heart failure (HF)[22].Taken together, these studies indicate that sST2 
has the potential to be a predictive CV biomarker in patients with acute myocardial infarction( AMI), heart failure( HF) and 
dyspnea. Thus far, serum or plasma IL-33 has been measured in CV diseases.  
In the role of the IL-33/ST2 pathway in inflammatory disease IL-33 was initially found in the nucleus of the high endothelial 
venules (HEV) of secondary lymphoid tissues (5). More recently, IL-33 expression has been reported in coronary artery 
smooth muscle cells [23], coronary artery endothelium [24], non-HEV endothelial cells [25], adipocytes [26] and cardiac 
fibroblasts suggesting that IL-33 may play a role in various CV disorders  [27]. 
Binding of IL-33 to theST2 receptor, in response to cardiac disease or injury, such as an ischemic event, elicits a 
cardioprotective effect resulting in preserved cardiac function. This cardioprotective IL-33 signal is counterbalanced by the 
level of soluble ST2, which binds IL-33 and makes it unavailable to the ST2 receptor for cardioprotective signaling. As a 
result, the heart is subjected to greater stress in the presence of high levels of soluble ST2. [28][29] 
The biological effects of IL-33 are limited by a soluble decoy from ST2 (sST2). Recent studies indicate a protective role for 
IL-33 and ST2L in atherosclerosis, obesity and cardiac remodeling. [30] 
In addition to its potential as a biomarker for adverse cardiovascular events, ST2 is considered to play a causal role in 
chronic cardiovascular diseases such as atherosclerosis and heart failure. Signaling of IL-33 via ST2 has been shown to 
be cardioprotective in mouse models of myocardial infarction, heart transplantation and cardiac hypertrophy and fibrosis. 
Furthermore, treatment with IL-33 reduced the development of plaques in atherosclerotic mice. [31] 
IL-33 has been also found to have protective effects in cardiovascular diseases. Recent studies have illustrated that IL-33 
attenuates cardiac fibrosis induced by increased cardiovascular load in mice (transaortic constriction). Since cardiac 
fibrosis is largely dependent on increased production of extracellular matrix by cardiac fibroblasts, we hypothesized that 
IL-33 directly inhibits pro-fibrotic activities of these cells. [32] 
IL-33 
) 
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Clinically, in patients with symptomatic heart failure(HF), elevated concentration of sST2 are strongly associated with 
severity of the diagnosis, and powerfully predict increased risk of complications, independent of other established or 
emerging biomarkers. Soluble ST2(sST2) testing has been shown to predict onset of symptomatic HF in patients with 
acute myocardial infarction, while in community-based subjects, sST2 values independently predict future HF, 
cardiovascular disease events, and mortality. [33] 
CONCLUSION 
A conclusive remark could be stated that the work on IL-33 is still in the beginning and extensive studies are needed to 
elucidate the exact role of this cytokine in obesity and atherogenic lipoprotein and their metabolic consequences in 
predicting cardiovascular diseases. 
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